Market Trends of Global Artemisinin Combination Therapy Industry
This section covers the major market trends shaping the Artemisinin Combination Therapy Market according to our research experts:
Artemether-Lumefantrine Segment is Expected to Witness Significant Growth Over the Forecast Period.
Artemether-Lumefantrine is a medication that combines the drugs artemether and lumefantrine.It is used to treat malaria caused by Plasmodium falciparum, which is not treatable with chloroquine. They were both developed in China. It is one of the drugs on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.
The World Health Organization says that Plasmodium falciparum malaria that is not complicated should be treated with a combination of artemisinin and lumefantrine.According to the study titled "Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Ethiopia: a systematic review and meta-analysis" published in May 2021, artemether-lumefantrine therapy is efficacious and safe in treating uncomplicated falciparum malaria in Ethiopia.
Also, the studied market is being driven by the growing number of malaria cases around the world.For instance, in 2022, the World Malaria Report stated that total funding for malaria research in 2021 was estimated at USD 3.5 billion, an increase from USD 3.3 billion in 2020 and USD 3.0 billion in 2019. The increase in funding for malaria research is expected to increase demand for artemether-lumefantrine research for malaria treatment, thereby driving the growth of the segment.
As this combination is used as the first-line drug for malaria in most countries, it is expected to cover a large share of the global artemisinin combination therapy market.
The Middle East and Africa Region is Expected to Witness a Significant Growth Over the Forecast Period.
The Middle East and Africa region are expected to witness growth over the forecast period, due to the rising investments by the developed countries and larger patient populations, coupled with the rising focus of the World Health Organization (WHO) to reduce the mortality rate of malaria in the African countries.
According to World Health Organization data, Sub-Saharan Africa will most likely continue to bear the burden of malaria in 2021, accounting for approximately 95% of all cases and 96% of all deaths.According to information released by the World Health Organization, mutations linked to partial artemisinin resistance, which is the first-line treatment for P. falciparum malaria with no complications, will be found in Rwanda in Africa in 2021.P. falciparum is the most prevalent malarial parasite in the region, accounting for an estimated 99% of all cases in Africa, according to the WHO. Also, as per the same source, children under the age of 5 are the most vulnerable group affected by malaria since they account for 67% (274 000) of all malaria deaths worldwide. These facts are indicative of the rising prevalence of malaria diagnoses in the Middle East and Africa. Thus, the increasing cases of malaria in the region require effective treatment, which is further expected to boost the growth of the market in the region over the forecast period.
Moreover, in August 2022, President Muhammadu Buhari inaugurated the Nigeria End Malaria Council (NEMC) in Abuja, projecting that the successful implementation of the council's agenda and savings from the estimated economic burden of the disease would save Nigeria about N687 billion in 2022 and N2 trillion by 2030. Such initiatives taken by the government in the region are expected to boost the growth of the market over the forecast period.
Thus, due to a high number of malaria cases and research, the region is expected to witness growth over the forecast period.
